Email updates

Keep up to date with the latest news and content from BMC Research Notes and BioMed Central.

Open Access Research article

Lung function monitoring in patients with duchenne muscular dystrophy on steroid therapy

Darlene L Machado1, Elaine C Silva1, Maria B D Resende1, Celso R F Carvalho2, Edmar Zanoteli13 and Umbertina C Reed1*

Author Affiliations

1 Department of Neurology, Medical School of the University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar 255, room 5131, Cerqueira Cesar, São Paulo, 05403900, Brazil

2 Department of Physical Therapy, Speech Therapy and Occupational Therapy, Medical School of the University of São Paulo, São Paulo, Brazil

3 Neuromuscular Division, Associação de Assistência à Criança Deficiente (AACD), São Paulo, Brazil

For all author emails, please log on.

BMC Research Notes 2012, 5:435  doi:10.1186/1756-0500-5-435

Published: 13 August 2012



Duchenne muscular dystrophy (DMD) is a sex-linked inherited muscle disease characterized by a progressive loss in muscle strength and respiratory muscle involvement. After 12 years of age, lung function declines at a rate of 6 % to 10.7 % per year in patients with DMD. Steroid therapy has been proposed to delay the loss of motor function and also the respiratory involvement.


In 21 patients with DMD aged between seven and 16 years, the forced vital capacity (FVC) and the forced expiratory volume in one second (FEV1) were evaluated at three different times during a period of two years.


We observed in this period of evaluation the maintenance of the FVC and the FEV1 in this group of patients independently of chronological age, age at onset of steroid therapy, and walking capacity.


The steroid therapy has the potential to stabilize or delay the loss of lung function in DMD patients even if they are non-ambulant or older than 10 years, and in those in whom the medication was started after 7 years of age.

Duchenne muscular dystrophy; Steroids; Vital forced capacity; Respiratory function tests; Myopathies